Join our daily newsletter At The Bell to receive exclusive market insights
LTR Pharma Ltd (ASX:LTP) has entered an access agreement with specialised health provider Men’s Health Downunder (MHDU) centred on the supply of its lead nasal spray product for erectile dysfunction.
The company aims to introduce the product, SPONTAN, to the market, while also gathering real-world patient data. For this, a partnership with MHDU – which is responsible for an Australia-wide network of pharmacists, GPs, nurses, and allied health professionals working around urological healthcare – will be a boon.
LTR Pharma will also have access to MHDU’s extensive referral network, which includes general practitioners, urologists, and sexual health clinics – with more than 1,000 patients seen annually through the latter.
MHDU founder and executive chairman Brad Butt said this agreement was an important step for both parties.
“This collaboration with LTR Pharma enhances our ability to provide innovative solutions for men’s health concerns,” he said.
“SPONTAN’s rapid-onset profile addresses a significant unmet need in erectile dysfunction treatment, complementing our multi-disciplinary and multi-modal approach to men’s
healthcare.”
LTR Pharma has been trading at 84 cents.
Join the discussion: See what HotCopper users are saying about LTR Pharma and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
